Curis, Inc. (NASDAQ:CRIS) Short Interest Up 82.0% in January

Curis, Inc. (NASDAQ:CRIS) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 81,700 shares, an increase of 82.0% from the December 31st total of 44,900 shares. Based on an average daily volume of 118,900 shares, the short-interest ratio is presently 0.7 days. Currently, 1.1% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Curis in a research report on Tuesday, December 10th.

Institutional Investors Weigh In On Curis

An institutional investor recently raised its position in Curis stock. Focused Wealth Management Inc raised its stake in shares of Curis, Inc. (NASDAQ:CRIS) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,204 shares of the biotechnology company’s stock after acquiring an additional 5,138 shares during the period. Focused Wealth Management Inc owned approximately 0.70% of Curis worth $181,000 as of its most recent SEC filing. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Curis Stock Up 2.9 %

Shares of CRIS traded up $0.09 during trading on Wednesday, reaching $3.22. 33,070 shares of the company traded hands, compared to its average volume of 224,571. Curis has a twelve month low of $2.86 and a twelve month high of $17.49. The stock has a market cap of $27.27 million, a PE ratio of -0.41 and a beta of 3.42. The stock has a 50-day simple moving average of $3.59 and a 200-day simple moving average of $4.62.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.